Medicaid officials in 3 states have received a green light from the federal government to form a drug-buying collaborative designed to negotiate lower prices from pharmaceutical manufacturers. The new Sovereign States Drug Consortium combines the drug-buying power of Maine, Vermont, and Iowa in an effort to pressure 58 different drug makers to lower their prices on >1300 medications used by Medicaid patients. The system has been in use in Maine for nearly a year, and officials there said that its Medicaid program has already saved >$1 million.
A key element of the plan involves limiting the role of pharmacy benefit managers to ensure that all the negotiated savings are passed on to the states. A group of 7 other states has formed a similar buying group called the National Medicaid Pooling Initiative, and officials of additional state Medicaid programs have expressed interest in forming similar consortia.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs